- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Optimer Pharmaceuticals Inc
+ Add to WatchlistOPTR:US
14.4400 USD 0.0100 0.07%As of 20:10:00 ET on 06/18/2013.
Snapshot for Optimer Pharmaceuticals Inc (OPTR)
| Open: | 14.4100 | Day's Range: | 14.1504 - 14.5900 | Volume: | 392,566 |
|---|---|---|---|---|---|
| Previous Close: | 14.4300 | 52wk Range: | 8.6400 - 16.8000 | 1-Yr Rtn: | -7.44% |
Key Statistics for OPTR
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -1.2000 |
| Est. EPS (USD) (12/2013) | -2.2170 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 703.53 |
| Shares Outstanding (M) | 48.72 |
| 30 Day Average Volume | 1,124,714 |
| Price/Book (mrq) | 6.5985 |
| Price/Sale (ttm) | 6.4365 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/31/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for OPTR
Company Profile & Key Executives for OPTR
Optimer Pharmaceuticals, Inc. discovers, develops, and commercializes anti infective products. Optimer's initial development efforts address products that treat gastrointestinal infections (GI), and related diseases, including diminished efficacy, serious adverse side effects, drug-to-drug interactions, difficult patient compliance, and bacterial resistance.
| Henry A McKinnell JrChairman/CEO | Stephen W WebsterChief Financial Officer |
| Eric SirotaChief Operating Officer | Meredith SchaumChief Compliance Ofcr/Gen Cnsl |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
OPTR News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page